1. Home
  2. EVC vs AUTL Comparison

EVC vs AUTL Comparison

Compare EVC & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Entravision Communications Corporation

EVC

Entravision Communications Corporation

N/A

Current Price

$6.50

Market Cap

683.9M

Sector

Industrials

ML Signal

N/A

Logo Autolus Therapeutics plc

AUTL

Autolus Therapeutics plc

N/A

Current Price

$1.41

Market Cap

596.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EVC
AUTL
Founded
1996
2014
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Broadcasting
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
683.9M
596.2M
IPO Year
2000
2025

Fundamental Metrics

Financial Performance
Metric
EVC
AUTL
Price
$6.50
$1.41
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
★ $8.75
AVG Volume (30 Days)
1.1M
★ 1.8M
Earning Date
11-05-2026
11-10-2026
Dividend Yield
★ 3.28%
N/A
EPS Growth
★ 47.59
N/A
EPS
★ 0.32
N/A
Revenue
★ $536,034,000.00
$10,120,000.00
Revenue This Year
N/A
$98.68
Revenue Next Year
N/A
$28.47
P/E Ratio
$19.02
★ N/A
Revenue Growth
N/A
★ 496.00
52 Week Low
$1.98
$1.18
52 Week High
$13.74
$2.58

Technical Indicators

Market Signals
Indicator
EVC
AUTL
Relative Strength Index (RSI) 43.29 31.30
Support Level $6.43 $1.38
Resistance Level $10.09 $1.73
Average True Range (ATR) 0.31 0.09
MACD 0.07 -0.01
Stochastic Oscillator 63.64 6.87

Price Performance

Historical Comparison
EVC
AUTL

About EVC Entravision Communications Corporation

Entravision Communications Corp owns and operates Spanish language television and radio stations in the United States. The Company also owns and operates a smaller group of television stations that broadcast English language programming and has operations that provide programmatic advertising technology and services. The Company has organized its operations into two reportable segments. Its media segment includes its television, radio, and digital marketing operations. Its advertising and technology services segment provides programmatic advertising and technology services. The company generates the majority of its revenue from the advertising and technology services segment. Geographically, the company generates the majority of its revenue from the United States.

About AUTL Autolus Therapeutics plc

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.

Share on Social Networks: